[O-31] 一般演題口演セッション31
治療創薬・再生医療１ E

[O-31-1] Long-term Safety and Efficacy of Patisiran in the Global Open-label Extension Study: 24-Month Data

^○植田 光晴¹, David Adams², Alejandra González-Duarte³, Elizabeth A Mauricio⁴, Thomas H Brannagan⁵, Teresa Coelho⁶, Jonas Wixner⁷, Hartmut Schmidt⁸, Erhan Berber⁹, Marianne Sweetser⁹, Matthew T White⁹, Jing Jing Wang⁹, Michael Polydefkis¹⁰ (1.熊本大学病院 脳神経内科, 2.National Reference Center for FAP (NNERF)/ APHP/ INSERM U 1195/ CHU Bicêtre, Le Kremlin Bicêtre, France, 3.Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico, 4.Mayo Clinic, Jacksonville, FL, USA, 5.Department of Neurology, Columbia University, New York City, NY, USA, 6.Centro Hospitalar Universitário do Porto, Portugal, 7.Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden, 8.University Hospital Muenster, Muenster, Germany, 9.Alnylam Pharmaceuticals, Cambridge, USA, 10.Johns Hopkins University, Baltimore, USA)